Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (TM) (CC-4047) and their relationship with venous thrombosis

M Streetly, B J Hunt, K Parmar, R Jones, J Zeldis, S Schey

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

We evaluated the serum/plasma levels of cytokines [interleukin (IL)-6, vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta 2] and markers of coagulation, fibrinolysis, endothelial and platelet activation during the first 4 wk of treatment with the thalidomide analogue Actimid(TM) (CC-4047) in 15 patients with relapsed/refractory myeloma. There was evidence of activation of endothelium (soluble vascular cell adhesion molecule, sVCAM), coagulation (prothrombin fragment 1 + 2, PF1 + 2) and fibrinolysis (D-dimers) but no evidence of platelet activation or endothelial cell damage in myeloma patients. These parameters were not affected by the use of CC-4047. Three of four patients with baseline D-dimers levels > 500 mu g/L subsequently developed deep vein thrombosis (DVT). The hypothesis that D-dimer level > 500 mu g/L may predict for those patients most at risk of thromboembolism with multiple myeloma undergoing treatment is worthy of further study
Original languageEnglish
Pages (from-to)293 - 296
Number of pages4
JournalEuropean Journal of Haematology
Volume74
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Dive into the research topics of 'Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (TM) (CC-4047) and their relationship with venous thrombosis'. Together they form a unique fingerprint.

Cite this